| INTRODUC TI ON
Catheter ablation (CA) is widely used for rhythm control in patients with atrial fibrillation (AF), with various studies showing that CA is superior to antiarrhythmic drugs (AAD) for rhythm control and the maintenance of sinus rhythm. 1 A rhythm control strategy is generally noninferior to a rate control strategy, but is associated with symptomatic benefits and improved functional capacity. 1 Hence, CA is commonly used as a management option in symptomatic AF patients where drugs are intolerant or ineffective. [2] [3] [4] [5] The ability to identify the patients likely to have a successful outcome following CA would aid decision making and help target the patients most likely to achieve a successful outcome.
Nonetheless, success after CA is determined by many clinical factors, some of which have been used to derive clinical scoring systems to help predict the outcome of CA. Even stroke risk stratification schemes, such as the CHADS 2 and CHA 2 DS 2 -VASc scores were predictors of AF recurrence post-CA, 6 as have other scores of arrhythmia progression or recurrence, such as the HATCH, BASE-AF 2 , APPLE, CAAP-AF, and ALARMEc score. [7] [8] [9] [10] [11] More recently, the MB-LATER has been described as a new simple clinical score that has better prediction of AF recurrence post-CA, compared to older scores. 12 However, all of these scores have been derived in Western populations and there are limited data on their independent validation and comparative predictive value in an
Asian population.
In this study, our aim was to compare the predictive ability of seven existing clinical scoring systems (HATCH, CHADS 2 , CHA 2 DS 2 -VASc, BASE-AF 2 , APPLE, CAAP-AF, and MB-LATER) in a large "all comers" Chinese cohort of AF patients undergoing CA, focused on the comparisons to the newest clinical score, MB-LATER. As far as we are aware, this is the largest "real world" cohort comparing various clinical scores for AF recurrence post-CA.
| ME THODS
We retrospectively enrolled 1423 consecutive symptomatic adult patients with nonvalvular AF who were refractory to ≥1 antiar- Baseline clinical data were acquired from patients' medical records from the hospital patient database. Paroxysmal AF (PAF) was defined as AF that spontaneously terminated within 7 days, persistent AF (PeAF) as AF that lasted ≥7 days or required cardioversion for termination, and longstanding PeAF (LSPeAF) as AF lasted >1 year. The term "nonparoxysmal" AF (NPAF) included PeAF and LSPeAF. Patients were refractory for at least one AAD or refused to take any AAD. All patients had at least one symptomatic AF episode recorded before the ablation procedure.
Clinical information was used to calculate the HATCH, CHADS 2 , CHA 2 DS 2 -VASc, BASE-AF 2 , APPLE, CAAP-AF, and MB-LATER clinical scores (see Table 3 ). Because one risk factor (normalized left atrial size) of the ALARMEc score 9 could not be provided by the cohort, this score was not tested in this study. Data of the ablation procedure were obtained from the operation records of the hospital.
Arrhythmia recurrence was defined as any symptomatic or as- the procedure without use of AAD was defined as late or very late recurrence respectively. In this study, we defined "recurrence" by including any late or very late recurrence.
| Preprocedural management
All patients received oral anticoagulants for more than 6 weeks, 3 and transoesophageal echocardiography (TEE) or left atria computed tomography (CT) was used to exclude left atrial thrombosis. The left atrium (LA) anteroposterior diameter (LAD) was measured as the LA size. The estimated glomerular filtration rate (eGFR) was calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula
Key findings
• Recurrence in AF patients postcatheter ablation (CA)
can be related to various clinical risk factors;
• The MB-LATER score performed as good as (or in some cases, better than) other clinical scores for the prediction of AF recurrence post-CA based on AUC (c-indexes) and DCA;
• Simple clinical risk scores (that any clinician can use in the everyday clinic) can assess the likelihood of recurrence of atrial fibrillation following catheter ablation.
The study shows how one of the new simple scores (MB-LATER) has good predictive value in identifying recurrence of AF postablation. Based on net reclassification and discrimination analysis, the MB-LATER score performed best for predicting AF recurrent postablation.
What's known
• Success after CA is determined by many clinical factors.
• Several clinical scoring systems have been derived to help predict the arrhythmia outcome of CA for AF.
What's new
• We show that the MB-LATER score is a simple and practical score that performs better or at least comparable to other scores for prediction of AF recurrence after CA.
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| Follow-up
In all patients, oral anticoagulants and amiodarone or propafenone were administrated postprocedurally for 3 months (blanking period). After then, oral anticoagulant was continued in patients with a CHA 2 DS 2 -VASc score of ≥2. Physical examination, 12-lead ECG and 24-hour Holter ECG were performed at discharge, and at 1, 3, 6 months and every 6 months thereafter. Additional ECG or 24-hour Holter was performed in patients who complained of symptoms suggestive of arrhythmia relapse.
Recurrence of AF was defined as our study endpoint, and once recurrence was confirmed, observation of the patient ended.
Patients without evidence of recurrence were followed up for a minimum of 12 months.
| Statistical analysis
Data were tested for normality by Kolmogorov-Smirnov test. All continuous variables were presented as mean ± standard deviation and categorical variables were summarized as percentages. Continuous variables were compared using unpaired Student's t test and categorical variables were compared using Chi-square test. The association of the clinical variables with AF recurrence was analysed using univariate and covariate Cox regression models. 
| RE SULTS
In total, 1423 patients were enrolled the study: 13 patients were excluded as 11 patients refused to accept follow-up examination and 2 required cardiac surgical repair because of cardiac tamponade.
Baseline characteristics of the study cohort (n = 1410) are shown in Table 1 . Mean age was 57.2 ± 11. The mean follow-up period was 20.7 ± 8.8 months. Recurrence occurred in 365 (27.9%) patients, with recurrence rates for PAF and NPAF being 18.6% and 50.5% respectively. We found no difference in recurrence rate between the use of two kinds of energy or different ablation catheters (see Table 1 ).
Univariate Cox regression analysis found that age, AF types, duration of AF history, ER, history of congestive heart failure, hypertension, previous stroke or transient ischaemic attack, ischaemic heart disease, AAD failure, LAD, left ventricular ejection fraction (LVEF) and eGFR were risk factors of AF recurrence after ablation (see Table 2 ). All 7 clinical risk scores had significant predictive ability of AF recurrence after ablation (all P < 0.001).
Using covariate regression analysis of risk factors significant on univariate analysis, only age (HR 0.98, CI 0.97-0.99, P < 0.01), AF (HR 0.97, CI 0.97-0.98, P < 0.01), and ER (HR 3.12, CI 2.48-3.93, P < 0.01) were independent risk factors of AF recurrence(see Table 2 ). 
| Predictive ability of clinical scores
All clinical scores had significant predictive value for AF recurrence after ablation (see Table 4 ). The MB-LATER score had significantly TA B L E 4 AUC comparisons for the MB-LATER, against other clinical scores F I G U R E 1 Area under the curve (AUC) of the MB-LATER score and comparisons to other scores. AUC, area under curve; ROC, receiver operating characteristic better AUC for AF recurrence compared to the HATCH, CHADS 2 , and CHA 2 DS 2 -VASc scores, but was similar to the APPLE, CAAP-AF, and BASE-AF 2 score (see Table 4 and Figure 1 ). For the BASE-AF 2 score, there were no significant differences in the predictive ability compared to the APPLE and MB-LATER scores but the score's predictive ability was significantly better compared to the CAAP-AF, HATCH, CHADS 2 , and CHA 2 DS 2 -VASc scores (P < 0.05).
Based on NRI and IDI, the MB-LATER score significantly improved prediction of AF recurrence after ablation compared to the other six scores (see Table 5 ). Relative to other six scores, the use of the MB-LATER score would result in a NRI of 30%-82.6% (all P < 0.01) and IDI of 2.6%-18.6% (all P < 0.01) for predicting AF recurrence in our cohort.
The clinical usefulness was evaluated using the decision curve analyses, as presented in Figure 2 . The potential benefit of being guided by a score classification is linked to the assumed threshold for intervention. The MB-LATER showed similar clinical usefulness as the BASE-AF 2 , APPLE, CAAP-AF but was better than HATCH score on DCA.
In terms of survival analysis, the percentage of AF recurrence in patients with a MB-LATER score of 0, 1, 2, 3, 4, 5, 6 was 12.5%, 15.2%, 39.2%, 55.9%, 69.6%, and 100% respectively (Log Rank, P < 0.01). Using a cut-off score of 2, as shown in Figure 3 , the AF recurrence risk was increased by 52.1% in patients with a MB-LATER ≥2.0 (HR 1.52, CI = 1.32-1.76, P < 0.01). Figure 4 shows that, when compared to patients with an APPLE score <2, those patients with an APPLE score ≥2 had a 35.3% increased AF recurrence risk (HR F I G U R E 2 Decision curve analysis (DCA) of the MB-LATER and other scores. DCA, decision curve analysis
Kaplan-Meier analysis of the MB-LATER score using a cut off of 2 points. AT, atrial tachycardia; AFL, atrial fibrillation or flutter
Kaplan-Meier analysis of the APPLE score using a cut off of 2 points. AT, atrial tachycardia; AFL, atrial fibrillation or flutter 1.35, CI = 1.25-1.46, P < 0.01) and survived with more AT/AFL recurrence (Log Rank, P < 0.01).
| D ISCUSS I ON
In this study, our principal findings are as follows: (a) recurrence after CA was high (27.9%) especially in NPAF patients, and was related to As far as we are aware, this is the largest "real world" cohort comparing various published clinical scores for AF recurrence post-CA.
Unlike the derivation cohorts of the BASE-AF2, 8 ALARMEc, 9 APPLE, 10 CAAP-AF, 11 or MB-LATER 12 scores, which used only radiofrequency or freezing energy, our cohort included various approaches used in the "real world" setting, including different energy sources and force contact catheters. We found no significant difference in recurrence rate between the use of two kinds of energy or different ablation catheters, consistent with recent reports. [16] [17] [18] Of note, electrical or drug cardioversion were predictors of AF recurrence, consistent with a worse underlying AF substrate. 18, 19 We found that only age, AF types, CHF, BMI, ER, LAD, and eGFR were independent risk factors for AF recurrence on multivariate analysis, as previously reported. [20] [21] [22] All clinical scores tested showed significant predictive ability for AF recurrence after ablation with the AUC ranging from 0.57 to 0.75. Of note, age ≥75 years, diabetes mellitus and chronic obstructive pulmonary disease were not risk factors of AF recurrence in our cohort, but the proportion of patients age ≥75 years was small (4.6%).
The HATCH score was first derived to predict the progression from PAF to PeAF, 7 and has also been shown to be a useful predictor of new-onset AF. 23, 24 Both the CHADS 2 and CHA 2 DS 2 -VASc scores have utility in predicting AF-related stoke outcomes and guiding anticoagulation treatment, while their predictive value for AF recurrence was modest. 6 Indeed, the AUC of the HATCH, CHADS 2 , and CHA 2 DS 2 -VASc scores in our cohort were all approximately 0.57, with only modest predictive ability for AF recurrence post-CA (see Figure 1 ).
Akin to a previous report, 25 ER was strongly associated with AF recurrence as was AF type and LA enlargement. 26 Although not all components of the BASE-AF 2, 8 APPLE, 10 CAAP-AF, 11 or MB-LATER 12 scores were significant predictors of AF recurrence in our (Asian) cohort, the AUC of scores overall were all approximately 0.7, suggesting good predictive ability for AF recurrence.
Reclassification and discrimination was better with the MB-LATER score, which increased the NRI (for 30%-82.6%) and IDI (for 2.6%-18.6%) in predicting the AF recurrence postablation compared to the other six scores. A model that had much greater specificity but slightly lower sensitivity would have a higher AUC but would be a poorer choice for clinical practice. 27 In addition, based on DCA, the MB-LATER demonstrated similar net benefit in predicting AF recurrence as the BASE-AF 2 , APPLE, CAAP-AF scores and higher decision ability on AF recurrence than the HATCH score (see Figure 2) . Although the MB-LATER score was derived to predict the very late (more than 1 year) AF recurrence post-CA, our results suggest it also performs well in predicting AF recurrence in the earlier course post-CA, excluding the blanking period. Indeed, patients with a MB-LATER score of ≥2 had a 52.1% greater risk of AF recurrence postablation in our cohort, compared to those with a MB-LATER score of <2 (see Figure 3) . Thus, the MB-LATER score can be used to predict AF recurrence postablation, which could help decision making on continuing AADs or when counselling the patient of the possibility of a second ablation procedure.
As an alternative to MB-LATER, the APPLE score may be another option. Compared to the CAAP-AF score, the APPLE score has been validated in three different cohorts, and can be used to predict AF recurrence before the procedure. 10, 12, 28 Patients with an APPLE score ≥2 had an increased 35.3% AF recurrence risk postablation in our cohort, compared to those with score <2 (see Figure 4 ).
| Study limitations
This was a retrospective, observational, single centre study with associated limitations. Coding errors might happen when ascertaining comorbidities. Confirmation of recurrence used the symptoms, ECG or Holter ECG records, but some recurrences between the follow-up visits, especially if asymptomatic, might have been missed. Another scoring system, the ALARMEc score 9 was not tested in this study as we were unable to assess the LA size index in this cohort. The study was not powered to provide useful insights into the different energy sources or contact catheters; hence, recurrences may have many explanations beyond patient characteristics, such as operator or technology learning curves.
Finally, our remit was to examine a broad "real world" clinical practice scenario and the application of the clinical scores to assess the likelihood of recurrence postablation (and not focus on method of ablation, type of AF, etc.); thus, we have studied "all-comers" cohort, that has included a minority of re-do procedures and some patients undergoing cryoablation, reflecting clinical practice in most ablation centres.
| CON CLUS ION
Based on net reclassification and discrimination analysis, the MB-LATER score performed best for predicting AF recurrent postablation. This simple clinical risk score (that any clinician can use in the everyday clinic) may help assess the likelihood of recurrence of AF following catheter ablation. 
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